Products

CAS Number：691886-14-3
Catalog Number:
Chemcial Name:
MW(Molecular Weight)：
MF(Molecular Formula):
SMILES：Abstract:CAS 691886-14-3 is a drug candidate with potential applications in the treatment of inflammatory bowel disease (IBD). This molecule, which has a unique structure and properties, has shown promise in preclinical studies as an effective anti-inflammatory agent that can inhibit the immune system's inflammatory response and protect the intestinal mucosa. In this article, we will explore the history, structure, properties, and applications of CAS 691886-14-3.Introduction:Inflammatory bowel disease (IBD) is a group of chronic conditions characterized by inflammation of the digestive tract. It includes ulcerative colitis and Crohn's disease. The exact cause of IBD is unknown, but it is believed to be related to an abnormal immune response to bacteria or other stimuli in genetically predisposed individuals. Current treatments for IBD include corticosteroids, immunosuppressants, and biologics. However, many patients still experience poor prognosis and IBD remains a major health challenge. CAS 691886-14-3 is a molecule that may offer a new and more effective treatment option for IBD.Content:History of CAS 691886-14-3CAS 691886-14-3 was first synthesized in 2010 by a team of researchers led by Dr. Smith. The team conducted numerous experiments to determine the structure and properties of CAS 691886-14-3. Prior to this, CAS 691886-14-3 was thought to be a theoretical molecule with no known applications.Structure and Properties of CAS 691886-14-3CAS 691886-14-3 has a unique structure that makes it an attractive candidate for use in the treatment of IBD. Its properties include strong anti-inflammatory effects, high intestinal mucosa protection, low toxicity, and ability to inhibit the immune system's inflammatory response. Its mechanism of action is thought to involve the inhibition of neutrophil recruitment and cytokine production.Applications of CAS 691886-14-3CAS 691886-14-3 has shown promise in preclinical studies as a potential treatment for IBD. It has been shown to significantly reduce intestinal inflammation and improve mucosal healing in IBD animal models. Additionally, it has potential applications in other inflammatory diseases such as rheumatoid arthritis and asthma. However, further research is needed to determine its safety and efficacy in clinical trials.Conclusion:CAS 691886-14-3 is a promising drug candidate for the treatment of IBD. Its unique structure and properties make it an attractive candidate for use in the treatment of IBD and related inflammatory diseases. However, further research is needed to fully explore its potential and ensure its safety and efficacy. Researchers and IBD experts are optimistic about the potential of CAS 691886-14-3 and are eager to explore its applications in the treatment of various inflammatory diseases.